Genmab As Stock Price History
| GMAB Stock | USD 20.80 0.42 1.98% |
Below is the normalized historical share price chart for Genmab AS extending back to June 01, 2009. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Genmab AS stands at 20.80, as last reported on the 18th of January 2025, with the highest price reaching 21.03 and the lowest price hitting 20.75 during the day.
If you're considering investing in Genmab Stock, it is important to understand the factors that can impact its price. Genmab AS holds Efficiency (Sharpe) Ratio of -0.0714, which attests that the entity had a -0.0714% return per unit of risk over the last 3 months. Genmab AS exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Genmab AS's Risk Adjusted Performance of (0.06), market risk adjusted performance of 1.67, and Standard Deviation of 1.82 to validate the risk estimate we provide.
At present, Genmab AS's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 42.6 B, whereas Common Stock Total Equity is forecasted to decline to about 52.4 M. . At present, Genmab AS's Price Book Value Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Price To Operating Cash Flows Ratio is expected to grow to 28.58, whereas Price To Sales Ratio is forecasted to decline to 9.33. Genmab Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of June 2009 | 200 Day MA 25.4894 | 50 Day MA 21.3442 | Beta 0.859 |
Genmab |
Sharpe Ratio = -0.0714
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GMAB |
Estimated Market Risk
| 1.85 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genmab AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding Genmab AS to a well-diversified portfolio.
Price Book 2.9143 | Enterprise Value Ebitda 11.1973 | Price Sales 0.7277 | Shares Float 62.8 M | Wall Street Target Price 36.5556 |
Genmab AS Stock Price History Chart
There are several ways to analyze Genmab Stock price data. The simplest method is using a basic Genmab candlestick price chart, which shows Genmab AS price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | November 11, 2024 | 23.2 |
| Lowest Price | December 16, 2024 | 20.02 |
Genmab AS January 18, 2025 Stock Price Synopsis
Various analyses of Genmab AS's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Genmab Stock. It can be used to describe the percentage change in the price of Genmab AS from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Genmab Stock.| Genmab AS Price Daily Balance Of Power | (1.50) | |
| Genmab AS Price Rate Of Daily Change | 0.98 | |
| Genmab AS Price Action Indicator | (0.30) | |
| Genmab AS Accumulation Distribution | 14,914 |
Genmab AS January 18, 2025 Stock Price Analysis
Genmab Stock Price History Data
The price series of Genmab AS for the period between Sun, Oct 20, 2024 and Sat, Jan 18, 2025 has a statistical range of 3.64 with a coefficient of variation of 4.83. Under current investment horizon, the daily prices are spread out with arithmetic mean of 21.71. The median price for the last 90 days is 21.72. The company completed 5:1 stock split on 1st of May 2018.| Open | High | Low | Close | Volume | ||
| 01/17/2025 | 20.85 | 21.03 | 20.75 | 20.80 | 1,120,112 | |
| 01/16/2025 | 20.93 | 21.26 | 20.70 | 21.22 | 2,663,041 | |
| 01/15/2025 | 20.39 | 20.61 | 19.89 | 20.23 | 1,836,415 | |
| 01/14/2025 | 22.00 | 22.08 | 21.60 | 21.64 | 1,003,220 | |
| 01/13/2025 | 21.64 | 21.74 | 21.32 | 21.72 | 955,011 | |
| 01/10/2025 | 22.05 | 22.24 | 22.00 | 22.15 | 895,112 | |
| 01/08/2025 | 22.15 | 22.21 | 21.83 | 22.19 | 602,971 | |
| 01/07/2025 | 22.19 | 22.28 | 22.05 | 22.18 | 1,050,504 | |
| 01/06/2025 | 21.48 | 22.02 | 21.44 | 21.86 | 826,155 | |
| 01/03/2025 | 21.15 | 21.56 | 21.12 | 21.47 | 839,054 | |
| 01/02/2025 | 21.13 | 21.20 | 20.87 | 21.00 | 1,021,286 | |
| 12/31/2024 | 20.77 | 21.14 | 20.61 | 20.87 | 490,651 | |
| 12/30/2024 | 20.82 | 20.88 | 20.69 | 20.77 | 901,929 | |
| 12/27/2024 | 20.87 | 21.12 | 20.81 | 21.02 | 950,621 | |
| 12/26/2024 | 20.45 | 20.61 | 20.41 | 20.58 | 751,943 | |
| 12/24/2024 | 20.65 | 20.71 | 20.40 | 20.47 | 454,756 | |
| 12/23/2024 | 20.71 | 20.86 | 20.50 | 20.76 | 1,380,277 | |
| 12/20/2024 | 20.22 | 20.43 | 20.13 | 20.31 | 1,829,681 | |
| 12/19/2024 | 20.25 | 20.33 | 19.99 | 20.09 | 1,281,450 | |
| 12/18/2024 | 20.76 | 21.03 | 20.12 | 20.14 | 1,368,010 | |
| 12/17/2024 | 19.95 | 20.28 | 19.90 | 20.03 | 1,075,782 | |
| 12/16/2024 | 19.94 | 20.37 | 19.85 | 20.02 | 2,017,427 | |
| 12/13/2024 | 20.46 | 20.48 | 20.12 | 20.17 | 931,207 | |
| 12/12/2024 | 20.98 | 21.15 | 20.65 | 20.65 | 958,726 | |
| 12/11/2024 | 21.75 | 21.78 | 21.50 | 21.55 | 636,995 | |
| 12/10/2024 | 22.17 | 22.19 | 21.81 | 21.83 | 985,509 | |
| 12/09/2024 | 21.98 | 22.33 | 21.96 | 22.11 | 1,237,096 | |
| 12/06/2024 | 21.73 | 22.02 | 21.72 | 21.81 | 1,147,821 | |
| 12/05/2024 | 21.95 | 21.97 | 21.80 | 21.85 | 1,066,916 | |
| 12/04/2024 | 21.71 | 21.72 | 21.55 | 21.65 | 621,209 | |
| 12/03/2024 | 21.83 | 21.84 | 21.56 | 21.70 | 1,204,459 | |
| 12/02/2024 | 21.81 | 21.94 | 21.70 | 21.84 | 1,026,040 | |
| 11/29/2024 | 21.50 | 21.67 | 21.46 | 21.50 | 575,331 | |
| 11/27/2024 | 20.86 | 21.17 | 20.84 | 21.16 | 787,442 | |
| 11/26/2024 | 20.76 | 20.76 | 20.46 | 20.65 | 1,157,925 | |
| 11/25/2024 | 20.91 | 20.98 | 20.68 | 20.79 | 2,744,811 | |
| 11/22/2024 | 20.61 | 20.84 | 20.60 | 20.65 | 1,074,884 | |
| 11/21/2024 | 20.53 | 20.62 | 20.34 | 20.47 | 1,512,565 | |
| 11/20/2024 | 20.49 | 20.55 | 20.36 | 20.45 | 1,199,557 | |
| 11/19/2024 | 20.51 | 20.64 | 20.39 | 20.50 | 1,084,659 | |
| 11/18/2024 | 20.64 | 20.85 | 20.58 | 20.67 | 1,298,200 | |
| 11/15/2024 | 21.01 | 21.01 | 20.50 | 20.59 | 1,310,575 | |
| 11/14/2024 | 21.75 | 21.82 | 21.17 | 21.18 | 2,458,658 | |
| 11/13/2024 | 21.94 | 22.20 | 21.59 | 21.66 | 2,583,750 | |
| 11/12/2024 | 22.90 | 22.94 | 22.41 | 22.47 | 1,373,683 | |
| 11/11/2024 | 23.18 | 23.47 | 22.95 | 23.20 | 1,654,187 | |
| 11/08/2024 | 22.85 | 23.18 | 22.80 | 23.08 | 1,560,527 | |
| 11/07/2024 | 22.64 | 23.19 | 22.64 | 23.11 | 1,374,743 | |
| 11/06/2024 | 22.20 | 22.76 | 21.90 | 22.33 | 1,846,730 | |
| 11/05/2024 | 22.56 | 22.84 | 22.18 | 22.75 | 1,729,706 | |
| 11/04/2024 | 22.69 | 22.89 | 22.65 | 22.78 | 1,294,385 | |
| 11/01/2024 | 22.61 | 22.63 | 22.53 | 22.56 | 1,113,174 | |
| 10/31/2024 | 22.36 | 22.40 | 22.22 | 22.32 | 964,928 | |
| 10/30/2024 | 22.69 | 22.82 | 22.56 | 22.57 | 882,485 | |
| 10/29/2024 | 23.05 | 23.15 | 22.87 | 23.12 | 1,919,449 | |
| 10/28/2024 | 23.08 | 23.21 | 22.95 | 23.14 | 866,155 | |
| 10/25/2024 | 22.74 | 23.30 | 22.73 | 23.12 | 2,490,786 | |
| 10/24/2024 | 22.82 | 22.98 | 22.78 | 22.82 | 1,034,753 | |
| 10/23/2024 | 22.84 | 22.98 | 22.67 | 22.73 | 1,014,965 | |
| 10/22/2024 | 22.43 | 22.79 | 22.39 | 22.77 | 1,244,803 | |
| 10/21/2024 | 22.76 | 22.80 | 22.54 | 22.78 | 1,591,359 |
About Genmab AS Stock history
Genmab AS investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Genmab is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Genmab AS will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Genmab AS stock prices may prove useful in developing a viable investing in Genmab AS
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 75.8 M | 72 M | |
| Net Income Applicable To Common Shares | 6.4 B | 6.7 B |
Genmab AS Quarterly Net Working Capital |
|
Genmab AS Stock Technical Analysis
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Genmab AS Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Genmab AS's price direction in advance. Along with the technical and fundamental analysis of Genmab Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Genmab to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | 1.66 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance |